Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Lipoprotein(a) Concentrations Correlate With LDL-C in Diabetic Children

By LabMedica International staff writers
Posted on 30 Nov 2021
Cardiovascular disease (CVD) is a significant cause of mortality in those with diabetes. More...
Increased apolipoprotein B (apoB) and low-density lipoprotein cholesterol (LDL-C) have been shown in pediatric patients with diabetes with worsening glycemic control.

Lipoprotein(a) (Lp(a)) is a highly atherogenic lipoprotein that attaches to the apoB 100 moiety of LDL-C particles. Lp(a) is concentration is generally fully expressed by the second year in childhood. Lp(a) is highly heritable, with great concordance between parental levels.

Pediatric Endocrinologists at the University of Alabama School of Medicine (Birmingham, AL, USA) investigate the relationships between serum concentrations of Lp(a) with low-density lipoprotein cholesterol (LDL-C), race, body mass index (BMI), and HbA1c in children with diabetes. Their secondary aim was to evaluate the factors associated with elevated Lp(a) levels. The carried out across-sectional retrospective chart review of pediatric patients, ages 12-19 years, including 607 type 1 diabetes (T1D) and 93 type 2 diabetes (T2D); 49% were male, mean age was 13.2 ± 3.08 years, and the median Lp(a) was 8.00 mg/dL. In addition to standard lipid profile testing, the clinical laboratory also offered Vertical Auto Profile (VAP) testing through a commercial laboratory (Atherotech, Birmingham, AL, USA).

The investigators reported that the Black children had an increased relative risk (RR) of higher Lp(a) compared with White ones (RR 1.25). The median Lp(a) was significantly higher in Black people than in White people, 9 (6-14) versus 7 (5-11). Among patients with T1D, Black people had an increased relative risk of higher Lp(a) than White people (RR 1.23). In T2D, Black participants have 43% higher risk of having elevated Lp(a) than White participants (RR 1.43). In T1D, a 5 mg/dL increase in LDL-C results in 2% increase in Lp(a). In T2D, a 5 mg/dL increase of LDL-C results in an increase of Lp(a) by 3%. LDL-C and BMI are independently associated with Lp(a) (RR = 1.02 and RR = 0.98), respectively. Interestingly, patients with T1D had higher mean levels of Lp(a) despite having a lower BMI compared to children with T2D. Patients with T1D had higher mean HbA1c than those with T2D (9.14% [5.88-12.4] versus 8.27% [5.67-10.87]).

The authors concluded that Lp(a) is strongly associated with LDL-C in children with diabetes, indicating a reduction of LDL-C may additionally reduce cardiovascular risk by lowering Lp(a) levels. Black children with diabetes have a significant burden of Lp(a) concentrations compared with White children. It may be important to consider Lp(a) screening in children with diabetes for disease risk management and implement stricter therapeutic goals for LDL-C reduction. The study was published in the November, 2021 issue of Journal of the Endocrine Society.

Related Links:
University of Alabama School of Medicine
Atherotech



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Gastrointestinal Panel
Xpert® GI Panel
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026

Artificial intelligence (AI) is increasingly being integrated into molecular diagnostics, offering new approaches to interpreting complex genetic information, classifying cancers, and optimizing laboratory testing.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.